CanLiv, the Hepatobiliary Cancers Foundation, was founded in 2007 laying the groundwork to accelerate research and improve patient outcomes. In January 2015, CanLiv came under the umbrella of the Global Liver Institute, a new partnership focusing on patient-centered research, education, and health system delivery solutions.
Hepatocellular carcinoma (HCC) is a cancer that originates in the liver and is the most common and prevalent form of liver cancer. It typically strikes patients already with liver disease, particularly those with chronic Hepatitis B and C. The economic, societal, and medical toll is staggering and continues to be a burden.
[source: Ahmedin Jemal, DVM, PhD, Freddie, Bray, PdD, Melissa M. Center, MPH, Cacques Frlay, ME, Elizabeth Ward, PhD, David Forman, PhD Global Cancer Statistics; CA CANCER J CLIN 2011;61:69–90]
We bring diverse stakeholders together, unifying approaches to increase positive outcomes for liver cancer patients. Our initiatives center on patient-centric design to promote understanding and advance hope for cancer patients worldwide.